Abstract
Hyperuricemia (HUA), a metabolic disease caused by excessive production or decreased excretion of uric acid (UA), has been reported to be closely associated with a variety of UA transporters. Clerodendranthus spicatus (C. spicatus) is an herbal widely used in China for the treatment of HUA. However, the mechanism has not been clarified. Here, the rat model of HUA was induced via 10% fructose. The levels of biochemical indicators, including UA, xanthine oxidase (XOD), adenosine deaminase (ADA), blood urea nitrogen (BUN), and creatinine (Cre), were measured. Western blotting was applied to explore its effect on renal UA transporters, such as urate transporter1 (URAT1), glucose transporter 9 (GLUT9), and ATP-binding cassette super-family G member 2 (ABCG2). Furthermore, the effect of C. spicatus on plasma metabolites was identified by metabolomics. Our results showed that C. spicatus could significantly reduce the serum levels of UA, XOD, ADA and Cre, and improve the renal pathological changes in HUA rats. Meanwhile, C. spicatus significantly inhibited the expression of URAT1 and GLUT9, while increased the expression of ABCG2 in a dose-dependent manner. Metabolomics showed that 13 components, including 1-Palmitoyl-2-Arachidonoyl-sn-glycero-3-PE, Tyr-Leu and N-cis-15-Tetracosenoyl-C18-sphingosine, were identified as potential biomarkers for the UA-lowering effect of C. spicatus. In addition, pathway enrichment analysis revealed that arginine biosynthesis, biosynthesis of amino acids, pyrimidine metabolism and other metabolic pathways might be involved in the protection of C. spicatus against HUA. This study is the first to explore the mechanism of anti-HUA of C. spicatus through molecular biology and metabolomics analysis, which provides new ideas for the treatment of HUA.
Similar content being viewed by others
Introduction
UA (UA), as the final product of endogenous sources from self-damaged and dead cells or exogenous sources from high-purine diet, is mainly synthesized in the liver1. It is well known that hyperuricemia (HUA), defined as abnormal excess accumulation of UA, is caused by the overproduction of UA or the reduced excretion of UA from the kidneys and intestines2. According to recent epidemiological data, the prevalence of HUA is gradually increasing3. Particularly, it has been shown that the prevalence of HUA is 13.3% (19.4% in men and 7.9% in women) in China4 and 21% (21.2% in men and 21.6% in women) in the United States5. Of note, evidence indicates that HUA is not only a predisposing factor for gout, but also a crucial risk factor for the development of other metabolic diseases6. For instance, a multicenter retrospective real-world study showed that HUA was associated with dyslipidemia and chronic kidney disease both cross-sectionally and longitudinally7. More recently, another longitudinal cohort study reported that HUA significantly increased the risk of cardiovascular disease and all-cause mortality8. Undoubtedly, HUA deserves further attention.
Considering that HUA is a major risk factor for the progress of many metabolic diseases, it is possible that appropriate control of UA contributes to the prevention and treatment of these diseases. Currently, there are two main mechanisms by which UA-lowering drugs work: (1) Drugs that inhibit UA synthesis, such as allopurinol and febuxostat, are often recommended as first-line clinical drugs6. Nevertheless, clinical data indicate that these drugs have a series of side effects or poor efficacy, including hypersensitivity syndrome, worsening renal function and cardiovascular disease death9,10; (2) Drugs that promote UA excretion, including benzbromarone, have been used clinically for 30 years11. Whereas, it has been withdrawn from the European market due to its severe hepatotoxicity12. Consequently, under this case, safer and more effective drugs are needed to prevent HUA and related diseases.
Clerodendranthus spicatus (Thunb.) C. Y. Wu (C. spicatus), commonly known as ‘kidney tea’ in China and ‘Kumis kucing’ in Southeast Asia, is a perennial herb from the Lamiaceae family13,14. In the Chinese folk medicine, C. spicatus is frequently administered as a functional tea to prevent and treat various diseases, such as urinary lithangiuria, rheumatism, and gout13,15. Of note, preclinical studies have found that C. spicatus significantly reduce UA and blood urea nitrogen (BUN) levels, and dramatically improved renal tubular injury in rats with HUA nephropathy16. Increasing evidence suggests that C. spicatus and its compounds have numerous biological activities, including anti-tumor, anti-HUA, anti-gouty arthritis, analgesia, and anti-hyperglycemia13,17,18. However, according to literature surveys, there are fewer reports on the anti-HUA mechanisms of C. spicatus. Molecular biology analysis and metabolomics are two main approaches for understanding biological processes, and their combination will bring new information to pharmacological studies19,20. Hence, we explored the effects of C. spicatus on UA transporters and plasma metabolic profiles in HUA rats. This study is expected to provide a theoretical basis for the mechanisms by which C. spicatus ameliorates HUA and present new ideas for the treatment of HUA.
Materials and methods
Chemicals and reagents
Acetonitrile and formic acid (UPLC grade) were obtained from Merk (Darmstadt, Germany) and Sigma Aldrich (St. Louis, USA), respectively. Ultrapure water was obtained from Millipore-Q water purification system (Millipore, USA). All the other chemicals were purchased through market resources.
Sample of C. spicatus was purchased from Xishuangbanna (Yunnan Province, China) and authenticated by Professor Binghong Fei (Department of Traditional Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China). C. spicatus was crushed into powder, and 1500 g of the powder was accurately weighed and extracted with 1:10 of water by heating to reflux for 1 h. Such procedure was repeated twice, combined the two decoctions and concentrated to 1 g/ml. Benzbromarone was obtained from Heumann Pharma (Nuremberg, Germany).
Animal experiments and sample preparation
Animals treatments
This study protocol was approved by the Animal Care and Ethics Committee of the First Affiliated Hospital of Zhengzhou University (2022-KY-0627-001, Zhengzhou, China). All animal experiments were carried out in accordance with institutional ethical considerations and guidelines, and were also conducted according to ARRIVE guidelines. Forty male Sprague–Dawley rats (SPF grade, 220 ± 20 g) were obtained from Beijing SPF Laboratory Animal Technology. The animals were maintained in plastic cages with water and food available ad libitum. All animals were housed on a 12 h day-night cycle, and air-conditioner and venting system were used to keep the temperature and humidity at 25 ± 1 °C and 55 ± 5%, respectively. As previously described21, 10% fructose water (AMRESCO, USA) was used to induce HUA model. The rats were divided randomly into five groups (n = 8 per group). Among them, the control group (Con) was given normal drinking water, the model group (Mod) was given 10% fructose water, the positive group (Ben) was given 10% fructose water and treated with 20 mg·kg−1·d−1 benzbromarone, the C. spicatus group (CS) was given 10% fructose water and treated with 10.0 g·kg−1·d−1 C. spicatus, and the C. spicatus low-dose group (CSL) was given 10% fructose water and treated with 5.0 g·kg−1·d−1 C. spicatus22. Similarity, the Con group and the Mod group were gavaged with normal saline (0.9%). All drugs were administered via the stomach once a day.
Sample preparation
Serum was taken once a week after fasting 12 h (3000 rpm, 10 min, 4 °C) and the rats were sacrificed after 4 weeks. In addition, at week 4, a portion of the blood sample was placed in a centrifuge tube containing heparin sodium to obtain plasma for metabolomic studies. The serum levels of UA were detected using assay kit (BioSino Biotechnology & Science, Beijing, China), whereas xanthine oxidase (XOD), adenosine deaminase (ADA), BUN and creatinine (Cre) were measured with automatic chemistry analyzer (Chemray 240, Rayto Life and Analytical). Furthermore, the kidneys were excised on ice and fixed in neutral paraformaldehyde for 48 h. Then, formalin-fixed kidneys were cut at a thickness of 4 μm and stained with hematoxylin–eosin (HE). The slides were observed and photographed under a light microscope for the changes of kidney tissue structure.
RNA isolation and real-time PCR analysis
Kidney (100 mg) was homogenized with TRIzol Reagent (Invitrogen Life Technologies, Carlsbad, CA, lot number: 15596-026) to extract mRNA. Extracted mRNA was reverse-transcribed following the manufacturer protocol of a HiScript® II Reverse Transcriptase (Vazyme, Nanjing, China, lot number: R211-01). Quantitative real-time polymerase chain reaction (PCR) was carried out using ChamQ Universal SYBR qPCR Master Mix kit (Vazyme, Nanjing, China, lot number: Q711-02), and then fluorescence quantitative analysis was carried out using ABI7500 fluorescence quantitative analyzer produced by ABI Company. Additionally, the primers of genes urate transporter1 (URAT1), glucose transporter 9 (GLUT9), and ATP-binding cassette super-family G member 2 (ABCG2) refer to the relevant sequence information in the article by Zhao et al.23.
Measurement of protein expression of transporters
Western blotting analysis was performed as our research group previously described. Kidneys of rats were rinsed with PBS, lysed with radioimmunoprecipitation assay buffer and then centrifuged (12,000 rpm, 15 min, 4 °C). 60 μg of lysates were separated by 12% SDS–polyacrylamide gel electrophoresis, and then transferred to polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The membranes were blocked with 5% skimmed milk for 1 h at room temperature, and pre-incubated with one of the following antibodies overnight at 4 °C: anti-ABCG2 (1:200 dilution, Abcam, USA, lot number: sc-58222), anti-GLUT9 (1:1000 dilution, Merk, Germany, lot number: ABN407), anti-URAT1 (1:1000 dilution, biorbyt, UK, lot number: orb637320) and mouse-anti-β-actin antibody (1:5000, Proteintech, China, lot number: 66009-1-Ig). After incubation with the secondary antibody, the membrane was washed in TBST for 30 min, and the Bio-RAD exposure instrument was preheated for exposure before color development. Finally, the gray value of the protein band was analyzed by Image J software.
Chromatographic and mass spectrometric conditions
The separation was performed on a ACQUITY UPLC HSS T3 C18 column (2.1 mm × 100 mm, 1.8 μm) at 40 °C. The mobile phases consisted of 0.1% formic acid in water (solvent A) and acetonitrile (solvent B). The elution gradient is as follows: 0 min, 95%A; 11 min, 10%A; 12 min, 10%A; 12.1 min, 95%A; 14 min, 95%A, which was delivered at 0.4 mL/min. The volume of injection samples was fixed at 2 μL. The eluent was directly introduced to the mass spectrometer. Quality control samples (QC) are prepared by mixing sample extracts to monitor the reproducibility of analytical samples under the same processing method. In the process of instrument analysis, the quality control sample was inserted into every 8 detection analysis samples to monitor the repeatability of the analysis process. And by tandem mass spectrometry, electrospray ionization: the electrospray capillary voltage was 5500 V in positive ionization mode and 4500 V in negative ionization mode. Both capillary temperature and aux gas heater temperature were 500 °C. The ion source gas I, gas II and curtain gas stepped 55, 60, and 25 psi, respectively.
Data analysis
Data are represented as the mean ± SD. Statistical analyses were carried out with one-way ANOVA followed by Dunnett’s multiple comparison test to determine levels of significance using SPSS v 20.0 (IBM, Armonk, USA), and P < 0.05 was considered significant. Meanwhile, the graphs were made by GraphPad Prism 8.0 software.
By using multiple reaction monitoring of triple-quadrupole mass spectrometry, the metabolites were quantified and the characteristic ions as well as the signal strength were obtained. Then, imported the data into R software and performed multivariate data processing, including principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA). The variable importance in projection (VIP) of multivariate OPLS-DA model preliminarily filtrated the metabolites from various groups, and variables with VI P ≥ 1.0 and fold change ≥ 2 or ≤ 0.5 were selected for further data analysis. Finally, the screened differential metabolites were imported into kyoto encyclopedia of genes and genomes (KEGG) for enrichment analysis of metabolic pathways (www.kegg.jp/kegg/kegg1.html)24,25,26.
Results
Effects of C. spicatus on serum UA, XOD and ADA levels
The serum levels of UA were measured as a characteristic HUA index. As shown in Fig. 1A, 10% fructose-drinking caused a significant increase in serum UA levels (P < 0.01) within 7–28 d, indicating that the HUA model was successfully constructed. Conversely, the serum UA levels of the Ben group were obviously lower than those of the Mod group (P < 0.05 or P < 0.01) during the entire study, and the CS group showed significantly reduced serum UA levels (P < 0.05 or P < 0.01) during 14–28 d. In parallel, the serum UA levels of the CSL group were significantly reduced in 21–28 d (P < 0.05), but showed no significant difference during the first 7–14 d (P > 0.05). As key enzymes in purine metabolism, XOD and ADA are essential for the development of HUA27,28. Figure 1B illustrates that, compared with the Con group, serum XOD levels in the Mod group were significantly increased during 7–28 d (P < 0.01). On the 14–28 d of the experiment, the serum XOD levels of the Ben group were significantly lower than those of Mod group (P < 0.05). Of note, different doses of C. spicatus could attenuate the serum XOD levels in HUA rats. Particularly, compared with the Mod group, the serum XOD levels of the CS group were notably reduced (P < 0.05 or P < 0.01) on days 7, 21 and 28, and the CSL group were significantly decreased on day 28 (P < 0.05). Furthermore, it could be seen from Fig. 1C that the serum ADA levels in the Mod group were significantly higher than those in the Con group (P < 0.05). However, different doses of C. spicatus could reduce ADA levels in HUA rats to different degrees.
Effects of C. spicatus on kidney damage
Furthermore, the serum levels of BUNand Cre were measured as indicators of kidney damage. As shown in Fig. 2A, there was no significant difference (P > 0.05) in the BUN levels among groups during the administration period. Surprisingly, Fig. 2B showed that the serum Cre levels in the Mod group were significantly higher than those in the Con group during 21–28 d (P < 0.05), whereas CS treatment significantly decreased Cre levels at 28 d (P < 0.05).
Alongside, as shown in Fig. 2C, HE-stained kidney sections from the Con group revealed normal histology with glomeruli and tubules. Compared with the Con group, stained sections from the Mod group showed that the cytoplasm was lightly stained, the renal tubules were obviously dilated, and some nuclei were disorganized. Stained sections from the Ben group showed an obvious improvement of renal tubular dilation. Compared with the Mod group, improved morphologic structures of glomeruli and renal tubules were observed in the CS and CSL groups, suggesting that C. spicatus could improve kidney damage.
Effects of C. spicatus on UA transporter expression
Effects of C. spicatus on the expression of UA transporters in HUA rats were shown in Fig. 3A–D. Compared with the Con group, the expression of ABCG2 was significantly decreased (P < 0.01), while the expression of URAT1 and GLUT9 was significantly increased in the Mod group (P < 0.05 or P < 0.01). Notably, the protein expression of renal URAT1 and GLUT9 was remarkably reduced in the CS group (P < 0.05 or P < 0.01). Similarity, the BEN group showed a notable reduction in the expression of renal URAT1 (P < 0.01). Nevertheless, URAT1 and GLUT9 protein expression had no changes in the CSL group (P > 0.05). On the other hand, it was worthy to note that the expression of ABCG2 in the Ben, CS and CSL groups was significantly increased when compared with HUA rats (P < 0.01) (Fig. 3B–D).
In accordance with protein levels, the mRNA levels of GLUT9 and URAT1 were markedly increased in HUA rats compared with the Con group (P < 0.01) (Fig. 3F,G). Furthermore, CS treatment could significantly decrease the mRNA levels of GLUT9 and URAT1 in HUA rats (P < 0.05 or P < 0.01), whereas there were no notable changes in the CSL group (P > 0.05). Moreover, the mRNA levels of ABCG2 in HUA rats were significantly decreased compared with those in the Con group (P < 0.01), and the Ben, CS and CSL groups showed notably increased the mRNA levels of ABCG2 compared with the Mod group (P < 0.01) (Fig. 3E).
Multivariate statistical analysis of C. spicatus on HUA
The CS group exhibited a better UA-lowering advantage compare to the CSL group. Therefore, to determine the effects of C. spicatus on metabolic pathways, we analyzed serum metabolites in the Con, Mod, and CS groups. Firstly, we performed data evaluation on each sample. The total ion current (TIC) plots of the mixed samples were shown in Fig. S1. The TIC overlap between samples is high, and the retention time and peak intensity are consistent, indicating high stability and reliability of UPLC analysis (Fig. S2). Noteworthy, PCA analysis (Fig. 4A) showed that there was an obvious separation between the Con and Mod groups, while the CS group partially overlapped with the Mod group, but deviated from the Con group, which preliminarily indicated that C. spicatus improved the metabolic disorder after modeling. Furthermore, cluster analysis (Fig. 4B) showed that the metabolites mainly included amino acid and its metabolomics, organic acid and its derivatives, as well as benzene and substituted derivatives.
Identification of potential biomarkers for C. spicatus treatment
OPLS-DA was then applied to further identify potential biomarkers showing prominent concentration changes. As seen from Fig. 5A,B, the OPLS-DA results showed that the pairwise comparisons of the Con, Mod, and CS groups had obvious separation trends. S-plot analysis (Fig. 5C,D) further showed that the distribution of differential metabolites between groups (VIP ≥ 1.0 and fold change ≥ 2 or ≤ 0.5 were considered as the potential discriminant variables and identified as candidate biomarkers). Of interest, a total of 13 of the 67 biomarkers were simultaneously altered with opposing trends in Mod and CS groups (Table 1 and Fig. S3). Particularly, compared with the Mod group, the levels of 1-Palmitoyl-2-Arachidonoyl-sn-glycero-3-PE, PE (16:1e/14-HDoHE), PC (18:2(9Z,12Z)/P-18:1(11Z)), PC (18:1(9Z)/P-18:1(11Z)), PC (16:0/P-16:0), PC (18:2(9Z,12Z)/15:0), SM (d18:1/22:0), PE (22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-16:0), N-cis-15-Tetracosenoyl-C18-sphingosine, PC (O-16:0/18:1), N-nervonoyl-D-erythro-sphingosylphosphorylcholine and 1,2-Dioleoyl-sn-glycero-3-phosphocholine were significantly down-regulated in the CS group. Nevertheless, the levels of Tyr-Leu were markedly up-regulated in the CS group compared with the Mod group.
Pathway analysis of C. spicatus on HUA
Subsequently, all candidate biomarkers were analyzed for KEGG pathway enrichment. As a result, metabolic pathway enrichment analysis revealed that 20 pathways contributed to HUA, including arginine biosynthesis, biosynthesis of amino acids, pyrimidine metabolism, and glucagon signaling pathway (Fig. 6).
Discussion
Growing evidence has indicated that excessive consumption of fructose is involved in metabolic syndrome, chronic kidney disease and HUA29,30. Indeed, the metabolism of fructose stimulates AMP deaminase, which in turn increases the rate of purine degradation31. Furthermore, it has been reported that long-term intake of fructose inhibits the excretion of UA from the kidney, resulting in increased serum UA levels32. Nonetheless, the effect of short-term intake of fructose on kidney excretion of UA is not completely understood. In the present study, we found that the serum UA of the Mod group could maintain a significantly elevated level throughout the study (Fig. 1A). This result is also in line with the current findings by Wang33. Additionally, renal dysfunction in HUA rats was documented (Fig. 2A,B). There were no significant BUN changes between the Con and the Mod groups. However, compared with the Con group, serum Cre levels in the Mod were significantly increased on days 21–28. On the other hand, HE-stained kidney sections showed that the renal cytoplasm was lightly stained, the renal tubules were significantly expanded, and some nuclei were disorganized after drinking fructose water for 28 days. Overall, these findings suggest that short-term fructose-induced HUA may be associated with renal impairment.
Recently, the genome-wide association studies and some large meta-analyses have revealed that the UA transporters are closely related to HUA34,35. In the kidney, the UA transporters were mainly divided into two categories: UA reabsorption transporters and UA excretion transporters, which is mediated mainly by URAT1, GLUT9 and ABCG236,37. URAT1 is a 12-transmembrane domain protein, which regulates tubular reabsorption of UA through ion-exchange mechanism with organic anions on the luminal membrane of epithelial cells in the proximal convoluted tubule of the kidney38,39. In the kidney proximal tubule, GLUT9 transports UA into the serum through the basolateral membrane, and it is a high-capacity UA transporter that plays an important role in the homeostasis of serum UA levels40. As an ATP-binding cassette transporter 2, ABCG2 plays a crucial role in renal UA excretion, and increasing evidence shows that ABCG2 dysfunction is a risk factor for HUA41. As mentioned above, a series of transporters regulate the renal excretion of UA. In this study, the expression of URAT1 and GLUT9 was significantly increased, while the expression of ABCG2 was significantly decreased in HUA rats. In addition, the mRNA levels were consistent with the above protein levels. Consistent with the results, Yang et al.42 also found that fructose drinking could cause significant changes in the above-mentioned UA transporters. Previous study had indicated that 12 compounds isolated from C. spicatus can promote the excretion of UA at 10 μg/mL13. In the present study, compared with the Mod group, the protein expression of URAT1 and GLUT9 in the CS group was significantly reduced, whereas ABCG2 was significantly increased in the CS group. All the results suggested that C. spicatus significantly decreased serum UA levels in HUA rats possibly by regulating the expression URAT1, GLUT9 and ABCG2.
Metabolomics provides important clues for elucidating the pathophysiological mechanisms. With the advent and evolution of metabolomics’ technologies, the mechanisms studies related to HUA have developed rapidly. For example, Chen et al.43 found that arginine biosynthesis, galactose metabolism, TCA cycle and pyrimidine metabolism were the main metabolic pathways for Tongfengxiaofang in the treatment of HUA by metabolomics. Huang et al.44 used metabolomic approach to study the potential mechanism by which Er Miao Wan reduced UA, and found that these metabolites were mainly associated with glycerolipid metabolism, primary bile acid metabolism and purine metabolism. In the study, a total of 13 biomarkers were significant altered and the trend was reversed after C. spicatus treatment. Interestingly, Murota et al. found that oral administration of peptide containing Tyr-Leu had anti-HUA activity45. The present study found that Tyr-Leu was significantly increased in the CS group compared with the Mod group, suggesting that C. spicatus may exert UA-lowering effects by increasing Tyr-Leu. Further metabolic pathway analysis revealed that the variations of these metabolites were mainly associated with arginine biosynthesis, pyrimidine metabolism, pentose and glucuronate interconversions, glycerolipid metabolism, glucagon signaling pathway, galactose metabolism, folate biosynthesis, citrate cycle (TCA cycle), and biosynthesis of amino acids. Notably, previous studies have shown that high levels of UA stress cardiomyocytes by accelerating arginine metabolism through the up-regulation of ornithine decarboxylase, which may be an important factor in the development of HUA-associated cardiac disease46. Surprisingly, purine metabolism, as the terminal pathway for UA production, was not screened in this experiment, suggesting that C. spicatus may exert its UA-lowering effects through other mechanisms.
Conclusion
The present study demonstrated the anti-HUA property of C. spicatus in a classical rat model of HUA and highlighted its potential mechanisms by an integrated approach of molecular biology analysis and metabolomics. In conclusion, C. spicatus protects rats from HUA via improving renal function, regulating UA transporters (URAT1, GLUT9, and ABCG2) and remodeling metabolic disorders. This research will lay a theoretical foundation for the use of C. spicatus as a UA-lowering drug. However, the molecular mechanism needs to be further explained and enriched.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- HUA:
-
Hyperuricemia
- UA:
-
Uric acid
- C. spicatus :
-
Clerodendranthus spicatus
- URAT1:
-
Urate transporter1
- GLUT9:
-
Glucose transporter 9
- ABCG2:
-
ATP-binding cassette super-family G member 2
- XOD:
-
Xanthine oxidase
- ADA:
-
Adenosine deaminase
- BUN:
-
Urea nitrogen
- Cre:
-
Creatinine
- HE:
-
Hematoxylin–eosin
- PCR:
-
Polymerase chain reaction
- QC:
-
Quality control samples
- PCA:
-
Principal component analysis
- OPLS-DA:
-
Orthogonal partial least squares discriminant analysis
- VIP:
-
Variable importance in projection
- TIC:
-
Total ion current
References
Yanai, H., Adachi, H., Hakoshima, M. & Katsuyama, H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int. J. Mol. Sci. https://doi.org/10.3390/ijms22179221 (2021).
Ogura, M. et al. Increase of serum uric acid levels associated with APOE ε2 haplotype: A clinico-genetic investigation and in vivo approach. Hum. Cell 34, 1727–1733. https://doi.org/10.1007/s13577-021-00609-w (2021).
Yip, K., Cohen, R. E. & Pillinger, M. H. Asymptomatic hyperuricemia: Is it really asymptomatic?. Curr. Opin. Rheumatol. 32, 71–79. https://doi.org/10.1097/bor.0000000000000679 (2020).
Liu, R. et al. Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: A systematic review and meta-analysis. Biomed. Res. Int. 2015, 762820. https://doi.org/10.1155/2015/762820 (2015).
Zhu, Y., Pandya, B. J. & Choi, H. K. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheumatol. 63, 3136–3141. https://doi.org/10.1002/art.30520 (2011).
Zhu, C., Sun, B., Zhang, B. & Zhou, Z. An update of genetics, co-morbidities and management of hyperuricaemia. Clin. Exp. Pharmacol. Physiol. 48, 1305–1316. https://doi.org/10.1111/1440-1681.13539 (2021).
Pang, S. et al. Hyperuricemia prevalence and its association with metabolic disorders: A multicenter retrospective real-world study in China. Ann. Transl. Med. 9, 1550. https://doi.org/10.21037/atm-21-5052 (2021).
Li, L. et al. Early onset of hyperuricemia is associated with increased cardiovascular disease and mortality risk. Clin. Res. Cardiol. 110, 1096–1105. https://doi.org/10.1007/s00392-021-01849-4 (2021).
Sung, Y. Y., Yuk, H. J. & Kim, D. S. Saengmaeksan, a traditional herbal formulation consisting of Panax ginseng, ameliorates hyperuricemia by inhibiting xanthine oxidase activity and enhancing urate excretion in rats. J. Ginseng Res. 45, 565–574. https://doi.org/10.1016/j.jgr.2021.01.001 (2021).
Cuenca, J. A. et al. Febuxostat and cardiovascular events: A systematic review and meta-analysis. Int. J. Rheumatol. 2019, 1076189. https://doi.org/10.1155/2019/1076189 (2019).
Sung, Y. Y. & Kim, D. S. Eggshell membrane ameliorates hyperuricemia by increasing urate excretion in potassium oxonate-injected rats. Nutrients. https://doi.org/10.3390/nu13103323 (2021).
Azevedo, V. F., Kos, I. A., Vargas-Santos, A. B., da Rocha Castelar Pinheiro, G. & Dos Santos Paiva, E. Benzbromarone in the treatment of gout. Adv. Rheumatol. 59, 37. https://doi.org/10.1186/s42358-019-0080-x (2019).
Chen, W. D. et al. “Kidney Tea” and its bioactive secondary metabolites for treatment of gout. J. Agric. Food Chem. 68, 9131–9138. https://doi.org/10.1021/acs.jafc.0c03848 (2020).
Ma, G. X. et al. Four new phenolic acid with unusual bicycle [2.2.2] octane moiety from Clerodendranthus spicatus and their anti-inflammatory activity. Fitoterapia 105, 61–65. https://doi.org/10.1016/j.fitote.2015.06.010 (2015).
Li, Q. et al. Clerodens E-J, antibacterial caffeic acid derivatives from the aerial part of Clerodendranthus spicatus. Fitoterapia 114, 110–114. https://doi.org/10.1016/j.fitote.2016.08.021 (2016).
Wu, S. et al. Clerodendranthus spicatus inhibits epithelial-mesenchymal transition of renal tubular cells through the NF-κB/Snail signalling pathway in hyperuricaemia nephropathy. Pharm. Biol. 61, 1274–1285. https://doi.org/10.1080/13880209.2023.2243086 (2023).
Li, Y. M., Xiang, B., Li, X. Z., Yan, Y. M. & Cheng, Y. X. New diterpenoids from Clerodendranthus spicatus. Nat. Prod. Bioprospect. 7, 263–267. https://doi.org/10.1007/s13659-017-0128-8 (2017).
Zhu, C., Niu, H., Nie, A. & Bian, M. Bioactivity-guided separation of potential α-glycosidase inhibitor from Clerodendranthus spicatus based on HSCCC coupled with molecular docking. Sci. Rep. 11, 6914. https://doi.org/10.1038/s41598-021-86379-9 (2021).
Imbert, A. et al. ProMetIS, deep phenotyping of mouse models by combined proteomics and metabolomics analysis. Sci. Data 8, 311. https://doi.org/10.1038/s41597-021-01095-3 (2021).
Salmond, G. P. & Fineran, P. C. A century of the phage: Past, present and future. Nat. Rev. Microbiol. 13, 777–786. https://doi.org/10.1038/nrmicro3564 (2015).
Wang, Y., Lin, Z. J., Nie, A. Z., Li, L. Y. & Zhang, B. Effect of Chinese herb chicory extract on expression of renal transporter Glut9 in rats with hyperuricemia. Zhongguo Zhong Yao Za Zhi 42, 958–963. https://doi.org/10.19540/j.cnki.cjcmm.2017.0029 (2017).
Zhu, C. et al. Study on the mechanism of Orthosiphon aristatus (Blume) Miq. in the treatment of hyperuricemia by microbiome combined with metabonomics. J. Ethnopharmacol. 317, 116805. https://doi.org/10.1016/j.jep.2023.116805 (2023).
Zhao, Z. A. et al. CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia. Acta Pharmacologica Sinica 43, 121–132. https://doi.org/10.1038/s41401-021-00640-5 (2022).
Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30. https://doi.org/10.1093/nar/28.1.27 (2000).
Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. Publ. Protein Soc. 28, 1947–1951. https://doi.org/10.1002/pro.3715 (2019).
Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587-d592. https://doi.org/10.1093/nar/gkac963 (2023).
Han, S. et al. Hypouricemic effects of extracts from Urtica hyperborea Jacq. ex Wedd. in hyperuricemia mice through XOD, URAT1, and OAT1. Biomed. Res. Int. 2020, 2968135. https://doi.org/10.1155/2020/2968135 (2020).
Zhang, D. et al. Natural xanthine oxidase inhibitor 5-O-caffeoylshikimic acid ameliorates kidney injury caused by hyperuricemia in mice. Molecules. https://doi.org/10.3390/molecules26237307 (2021).
Zhang, C., Li, L., Zhang, Y. & Zeng, C. Recent advances in fructose intake and risk of hyperuricemia. Biomed. Pharmacother. 131, 110795. https://doi.org/10.1016/j.biopha.2020.110795 (2020).
Bier, A. et al. High-fructose diet increases renal ChREBPβ expression, leading to intrarenal fat accumulation in a rat model with metabolic syndrome. Biology (Basel). https://doi.org/10.3390/biology11040618 (2022).
Kaneko, C. et al. Fructose suppresses uric acid excretion to the intestinal lumen as a result of the induction of oxidative stress by NADPH oxidase activation. Biochim. Biophys. Acta Gen. Subj. 559–566, 2017. https://doi.org/10.1016/j.bbagen.2016.11.042 (1861).
Nakagawa, T. et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Renal Physiol. 290, F625-631. https://doi.org/10.1152/ajprenal.00140.2005 (2006).
Wang, Y., Lin, Z., Zhang, B., Nie, A. & Bian, M. Cichorium intybus L. promotes intestinal uric acid excretion by modulating ABCG2 in experimental hyperuricemia. Nutr. Metab. Lond. 14, 38. https://doi.org/10.1186/s12986-017-0190-6 (2017).
Mandal, A. K. & Mount, D. B. The molecular physiology of uric acid homeostasis. Annu. Rev. Physiol. 77, 323–345. https://doi.org/10.1146/annurev-physiol-021113-170343 (2015).
Merriman, T. Genomic influences on hyperuricemia and gout. Rheum. Dis. Clin. N. Am. 43, 389–399. https://doi.org/10.1016/j.rdc.2017.04.004 (2017).
Keenan, R. T. The biology of urate. Semin. Arthritis Rheum. 50, S2-s10. https://doi.org/10.1016/j.semarthrit.2020.04.007 (2020).
Dai, H. et al. The active components of sunflower (Helianthus annuus L.) calathide and the effects on urate nephropathy based on COX-2/PGE2 signaling pathway and the urate transporter URAT1, ABCG2, and GLUT9. Front. Nutr. 8, 769555. https://doi.org/10.3389/fnut.2021.769555 (2021).
Zhao, T. et al. Novel human urate transporter 1 inhibitors as hypouricemic drug candidates with favorable druggability. J. Med. Chem. 63, 10829–10854. https://doi.org/10.1021/acs.jmedchem.0c00223 (2020).
Enomoto, A. et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417, 447–452. https://doi.org/10.1038/nature742 (2002).
Lüscher, B. P., Albrecht, C., Stieger, B., Surbek, D. V. & Baumann, M. U. Glucose transporter 9 (GLUT9) plays an important role in the placental uric acid transport system. Cells. https://doi.org/10.3390/cells11040633 (2022).
Vávra, J. et al. Functional characterization of rare variants in OAT1/SLC22A6 and OAT3/SLC22A8 urate transporters identified in a gout and hyperuricemia cohort. Cells. https://doi.org/10.3390/cells11071063 (2022).
Yang, Y. et al. Wuling San protects kidney dysfunction by inhibiting renal TLR4/MyD88 signaling and NLRP3 inflammasome activation in high fructose-induced hyperuricemic mice. J. Ethnopharmacol. 169, 49–59. https://doi.org/10.1016/j.jep.2015.04.011 (2015).
Chen, R. et al. Studies on effect of Tongfengxiaofang in HUM model mice using a UPLC-ESI-Q-TOF/MS metabolomic approach. Biomed. Chromatogr. 35, e5118. https://doi.org/10.1002/bmc.5118 (2021).
Huang, B., Hu, X., Wang, J., Li, P. & Chen, J. Study on chemical constituents of herbal formula Er Miao Wan and GC-MS based metabolomics approach to evaluate its therapeutic effects on hyperuricemic rats. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1118–1119, 101–108. https://doi.org/10.1016/j.jchromb.2019.04.032 (2019).
Murota, I. et al. Identification of antihyperuricemic peptides in the proteolytic digest of shark cartilage water extract using in vivo activity-guided fractionation. J. Agric. Food Chem. 62, 2392–2397. https://doi.org/10.1021/jf405504u (2014).
Weber, M., Schreckenberg, R. & Schlüter, K. D. Uric acid deteriorates load-free cell shortening of cultured adult rat ventricular cardiomyocytes via stimulation of arginine turnover. Biology. https://doi.org/10.3390/biology12010004 (2022).
Acknowledgements
The authors would like to thank all of the colleagues and students who contributed to this study.
Funding
This work was financially supported by the National Natural Science Foundation of China (82204701).
Author information
Authors and Affiliations
Contributions
Z.Z. and M.X.: Visualization, writing—original draft. M.B. and A.N.: participated in the experiments. B.S. and C.Z.: Supervision.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhou, Z., Xu, M., Bian, M. et al. Anti-hyperuricemia effect of Clerodendranthus spicatus: a molecular biology study combined with metabolomics. Sci Rep 14, 15449 (2024). https://doi.org/10.1038/s41598-024-66454-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-024-66454-7
- Springer Nature Limited